Rchr
J-GLOBAL ID：201401021716766573   Update date: Oct. 03, 2024

Tsubaki Masanobu

ツバキ マサノブ | Tsubaki Masanobu
Affiliation and department：
Tokushima Bunri University Faculty of Pharmaceutical Sciences at Kagawa Campus Department of Pharmacy

About Tokushima Bunri University Faculty of Pharmaceutical Sciences at Kagawa Campus Department of Pharmacy


Job title： Professor
Homepage URL  (1)： http://kaken.nii.ac.jp/d/r/30434856.ja.html
Research field  (1)： Pharmacology
Research keywords  (4)： 転移抑制 ,  抗癌剤耐性 ,  分子標的薬 ,  がん
Research theme for competitive and other funds  (4)：
  • 2020 - 2023 がん化学療法誘発末梢神経障害の機序解明と新規治療法の開発
  • 2016 - 2019 Application of molecular-targeted drugs for treatment of chemotherapy-induced peripheral neuropathy
  • 2015 - 2018 Identification of imatinib resistance factor and the therapeutic strategies to overcome resistance in chronic myeloid leukemia
  • 2012 - 2015 Investigation for the mechanism of anti-cancer drugs resistance and therapeutic strategy in multiple myeloma
Papers (123)：
  • Tomoya Takeda, Masanobu Tsubaki, Shuji Genno, Kana Tomita, Shozo Nishida. RANK/RANKL axis promotes migration, invasion, and metastasis of osteosarcoma via activating NF-κB pathway. Experimental cell research. 2024. 436. 2. 113978-113978
  • Tomoya Takeda, Masanobu Tsubaki, Shuji Genno, Kenta Tokunaga, Remi Tanaka, Shozo Nishida. HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple-negative breast cancer metastasis via the inhibition of CXCR4 expression. International journal of molecular medicine. 2023. 52. 3
  • Masayuki Shinkai, Motohiro Imano, Masashi Kohda, Tomoya Nakanishi, Yoko Hiraki, Takaomi Hagi, Hiroaki Kato, Osamu Shiraishi, Atsushi Yasuda, Masanobu Tsubaki, et al. Efficacy of palliative surgery for gastric cancer patients with peritoneal metastasis who still have residual peritoneal dissemination after chemotherapy. Langenbeck's archives of surgery. 2023. 408. 1. 291-291
  • Masanobu Tsubaki, Tomoya Takeda, Takuya Matsuda, Kana Kishimoto, Honoka Takefuji, Yuzuki Taniwaki, Misa Ueda, Tadafumi Hoshida, Kazufumi Tanabe, Shozo Nishida. Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy. Cancer cell international. 2023. 23. 1. 73-73
  • Masanobu Tsubaki, Tomoya Takeda, Yuuichi Koumoto, Takehiro Usami, Takuya Matsuda, Shiori Seki, Kazuko Sakai, Kazuto Nishio, Shozo Nishida. Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells. Cell proliferation. 2023. 56. 6. e13420
ｍore...
MISC (136)：
  • 木村智裕, 椿正寛, 武田朋也, 松田拓弥, 山本裕太, 森井悠介, 森井悠介, 西田升三. Overexpression of Serum/Glucocorticoid Regulated Kinase 1 is involved with proteasome inhibitor resistance in multiple myeloma. 日本がん分子標的治療学会学術集会プログラム・抄録集. 2021. 25th
  • 岸本佳奈, 椿正寛, 武田朋也, 松田拓弥, 山本裕太, 森井悠介, 森井悠介, 西田升三. Myeloma cells-secreted HGF accelerate the bone destruction via increased RANKL expression in bone marrow stromal cells and osteoblasts. 日本がん分子標的治療学会学術集会プログラム・抄録集. 2021. 25th
  • 椿正寛, 武田朋也, 松田拓弥, 山本裕太, 木村智裕, 森井悠介, 森井悠介, 西田升三. Rhosin inhibits tumor metastasis via suppression of Rho/YAP pathway. 日本がん分子標的治療学会学術集会プログラム・抄録集. 2021. 25th
  • 山本裕太, 椿正寛, 武田朋也, 松田拓弥, 木村智裕, 森井悠介, 森井悠介, 西田升三. Perifosine overcome MEK inhibitor resistance in PIK3CA-mutated colon cancer. 日本がん分子標的治療学会学術集会プログラム・抄録集. 2021. 25th
  • 森井悠介, 森井悠介, 椿正寛, 武田朋也, 松田拓弥, 山本裕太, 岸本佳奈, 西田升三. Akt inhibitor enhances the sensitivity to oxaliplatin and 5-fluorourasil in PIK3CA-mutated colon cancer. 日本がん分子標的治療学会学術集会プログラム・抄録集. 2021. 25th
ｍore...
Patents (9)：
ｍore...
Books (2)：
  • 新しい疾患薬理学
    南江堂 2018 ISBN:9784524403356
  • Alzheimer's disease pathogenesis-core concepts, shifting paradigms and therapeutic targets, Expression and cerebral function of amyloid precursor protein after rat traumatic brain injury
    Intech open access publisher 2011
Lectures and oral presentations  (112)：
  • Statinsによる悪性黒色腫でのRho経路阻害を介した転移抑制・延命効果
    (日本薬学会第134回年会 2014)
  • Nitrogen-containing bisphosphonatesによるRas/ERK及びRas/mTOR経路阻害を介したアポトーシス誘導機序
    (日本薬学会第134回年会 2014)
  • 多発性骨髄腫での抗がん剤耐性獲得機序-シグナル伝達因子活性化によるMDR1、Survivin及びBimの発現調節-
    (日本薬学会第134回年会 2014)
  • 多発性骨髄腫でのTNF-αオートクライン阻害によるmTOR及びNF-κB抑制を介した抗がん剤感受性増強効果
    (日本薬学会第134回年会 2014)
  • 多発性骨髄腫における多剤耐性獲得機序の解明
    (第36回日本分子生物学会年会 2013)
ｍore...
Professional career (1)：
  • 博士(薬学) (近畿大学)
Work history (3)：
  • 2024/03 - 現在 Tokushima Bunri University Faculty of Pharmaceutical Sciences at Kagawa Campus Department of Pharmacy Professor
  • 2018 - 2024/03 Kindai University Faculty of Pharmacy
  • 2013 - Kindai University Faculty of Pharmacy
Awards (1)：
  • 日本薬学会近畿支部 日本薬学会近畿支部奨励賞
Association Membership(s) (3)：
THE PHARMACEUTICAL SOCIETY OF JAPAN ,  THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER ,  THE JAPANESE CANCER ASSOCIATION
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM